Primary mesenchymal stem cells as a vaccine platform

Patent metadata

Field	Value
Publication number	US-10472647-B2
Application number	US-201314081740-A
Country	US
Kind code	B2
Filing date	Nov 15, 2013
Priority date	Dec 21, 2012
Publication date	Nov 12, 2019
Grant date	Nov 12, 2019

Abstract

Episomally transfected primary mesenchymal stem cells (MSC) express a polypeptide consisting of an antigenic polypeptide (e.g., one or more polypeptides) relating to a pathogen (e.g., one or more virus, bacterium, or parasite). The antigenic polypeptide can have the amino acid sequence of a natural polypeptide from the pathogen or an amino acid sequence differing from the natural sequence by one or more conservative amino acid substitutions. Uses and method for treating or preventing infections with episomally transfected primary MSC also are described.

First claim

We claim:

1. Episomally transfected primary mesenchymal stems cells (ETP-MSC) which episomally and transiently express at least one polypeptide having a sequence of a natural antigen from a pathogenic organism, or having a sequence that differs from the natural antigen by one or more conservative amino acid substitutions and sharing at least 50% sequence identity with the sequence of the natural antigen; and wherein the ETP-MSC elicit an antibody response to the antigen when the ETP-MSC are administered to a subject.

2. The ETP-MSC of claim 1 wherein the ETP-MSC episomally express a plurality of the antigens.

3. The ETP-MSC of claim 1 wherein the ETP-MSC episomally express about 2 to about 500 of the antigens.

4. The ETP-MSC of claim 1 wherein the ETP-MSC episomally express antigens from a plurality of pathogens.

5. The ETP-MSC of claim 1 wherein the antigen is a polypeptide from a virus.

6. The ETP-MSC of claim 1 wherein the MSC do not express an immune regulatory or costimulatory molecule.

7. The ETP-MSC of claim 1 wherein the antigen comprises HIV-1 gp120.

8. The ETP-MSC of claim 1 wherein the antigen is a polypeptide from a virus selected from the group consisting of: adenoviruses; papillomaviruses; hepadnaviruses; parvoviruses; pox viruses; Epstein-Barr virus; cytomegalovirus (CMV); herpes simplex viruses; roseolovirus; varicella zoster virus; filoviruses; paramyxoviruses; orthomyxoviruses; rhabdoviruses; arenaviruses; coronaviruses; human enteroviruses; hepatitis A virus; human rhinoviruses; polio virus; retroviruses; rotaviruses; flaviviruses; hepaciviruses; and rubella virus.

9. A pharmaceutical composition comprising the ETP-MSC of claim 1 in a pharmaceutically acceptable carrier.

Assignees

• The Administrators Of The Tulane Educational Fund

Inventors

• Tomchuck Suzanne L
• Norton Elizabeth B
• Garry Robert F
• Bunnell Bruce
• Clements John D

Classifications

• C12N2740/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N15/85 Primary

  for animal cells · CPC title

• Y02A50/491

  Cross-Sectional Technologies · mapped topic

• Y02A50/396

  Cross-Sectional Technologies · mapped topic

• Y02A50/469

  Cross-Sectional Technologies · mapped topic